In silico analysis reveals EP300 as a panCancer inhibitor of anti-tumor immune response via metabolic modulation.
Biomarkers, Tumor
Cohort Studies
Computer Simulation
E1A-Associated p300 Protein
/ genetics
Female
Glycolysis
Histone Acetyltransferases
/ genetics
Humans
Immunity
Immunotherapy
/ methods
Male
Middle Aged
Models, Theoretical
Mutation
/ genetics
Oxidative Phosphorylation
Squamous Cell Carcinoma of Head and Neck
/ genetics
Survival Analysis
Tumor Microenvironment
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 06 2020
10 06 2020
Historique:
received:
17
12
2019
accepted:
18
05
2020
entrez:
12
6
2020
pubmed:
12
6
2020
medline:
15
12
2020
Statut:
epublish
Résumé
The tumor immune microenvironment (TIME) of head and neck squamous cell carcinomas (HNSCC) and other solid malignancies is a key determinant of therapy response and prognosis. Among other factors, it is shaped by the tumor mutational burden and defects in DNA repair enzymes. Based on the TCGA database we aimed to define specific, altered genes associated with different TIME types, which might represent new predictive markers or targets for immuno-therapeutic approaches. The HNSCC cohort of the TCGA database was used to define 3 TIME types (immune-activated, immune-suppressed, immune-absent) according to expression of immune-related genes. Mutation frequencies were correlated to the 3 TIME types. Overall survival was best in the immune-activated group. 9 genes were significantly differentially mutated in the 3 TIME types with strongest differences for TP53 and the histone-acetyltransferase EP300. Mutations in EP300 correlated with an immune-activated TIME. In panCancer analyses anti-tumor immune activity was increased in EP300 mutated esophageal, stomach and prostate cancers. Downregulation of EP300 gene expression was associated with higher anti-tumor immunity in most solid malignancies. Since EP300 is a promoter of glycolysis, which negatively affects anti-tumor immune response, we analyzed the association of EP300 with tumor metabolism. PanCancer tumor metabolism was strongly shifted towards oxidative phosphorylation in EP300 downregulated tumors. In silico analyses of of publicly available in vitro data showed a decrease of glycolysis-associated genes after treatment with the EP300 inhibitor C646. Our study reveals associations of specific gene alterations with different TIME types. In detail, we defined EP300 as a panCancer inhibitor of the TIME most likely via metabolic modulation. In this context EP300 represents a promising predictive biomarker and an immuno-therapeutic target.
Identifiants
pubmed: 32523042
doi: 10.1038/s41598-020-66329-7
pii: 10.1038/s41598-020-66329-7
pmc: PMC7287052
doi:
Substances chimiques
Biomarkers, Tumor
0
E1A-Associated p300 Protein
EC 2.3.1.48
EP300 protein, human
EC 2.3.1.48
Histone Acetyltransferases
EC 2.3.1.48
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9389Références
Donnem, T. et al. Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 27, 225–232 (2016).
doi: 10.1093/annonc/mdv560
Turan, T. et al. Immune oncology, immune responsiveness and the theory of everything. J. Immunother. Cancer 6, 50 (2018).
pubmed: 29871670
pmcid: 5989400
doi: 10.1186/s40425-018-0355-5
Bindea, G. et al. Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer. Immunity 39, 782–795 (2013).
pubmed: 24138885
pmcid: 24138885
doi: 10.1016/j.immuni.2013.10.003
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
pubmed: 25594174
pmcid: 4856474
doi: 10.1016/j.cell.2014.12.033
Chimal-Ramírez, G. K., Espinoza-Sánchez, N. A. & Fuentes-Pananá, E. M. Protumor Activities of the Immune Response: Insights in the Mechanisms of Immunological Shift, Oncotraining, and Oncopromotion. J. Oncol. 2013 (2013).
Blankenstein, T., Coulie, P. G., Gilboa, E. & Jaffee, E. M. The determinants of tumour immunogenicity. Nat. Rev. Cancer 12, 307–313 (2012).
pubmed: 22378190
pmcid: 3552609
doi: 10.1038/nrc3246
Goodman, A. M. et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol. Cancer Ther. 16, 2598–2608 (2017).
pubmed: 28835386
pmcid: 5670009
doi: 10.1158/1535-7163.MCT-17-0386
Wang, S., He, Z., Wang, X., Li, H. & Liu, X.-S. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. eLife 8 (2019).
Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer genes. Nature 499, 214–218 (2013).
pubmed: 23770567
pmcid: 3919509
doi: 10.1038/nature12213
Hanna, G. J. et al. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight 3 (2018).
Zhao, F. et al. S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology 136, 176–183 (2012).
pubmed: 22304731
pmcid: 3403264
doi: 10.1111/j.1365-2567.2012.03566.x
Gutman, D. A. et al. The Digital Slide Archive: A Software Platform for Management, Integration, and Analysis of Histology for Cancer Research. Cancer Res. 77, e75–e78 (2017).
pubmed: 29092945
pmcid: 5898232
doi: 10.1158/0008-5472.CAN-17-0629
Thorsson, V. et al. The Immune Landscape of Cancer. Immunity 51, 411–412 (2019).
pubmed: 31433971
doi: 10.1016/j.immuni.2019.08.004
Krupar, R. et al. Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different. Virchows Arch. Int. J. Pathol. 465, 299–312 (2014).
doi: 10.1007/s00428-014-1630-6
Krupar, R. et al. Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma. Am. J. Pathol. 188, 72–83 (2018).
pubmed: 29107073
doi: 10.1016/j.ajpath.2017.09.013
Subramanian, A. et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell 171, 1437–1452.e17 (2017).
pubmed: 29195078
pmcid: 5990023
doi: 10.1016/j.cell.2017.10.049
Krupar, R. et al. Comparison of HPV prevalence in HNSCC patients with regard to regional and socioeconomic factors. Eur. Arch. Otorhinolaryngol. 271, 1737–1745 (2013).
pubmed: 24065189
doi: 10.1007/s00405-013-2693-8
Cooks, T., Harris, C. C. & Oren, M. Caught in the cross fire: p53 in inflammation. Carcinogenesis 35, 1680–1690 (2014).
pubmed: 24942866
pmcid: 4123652
doi: 10.1093/carcin/bgu134
Guo, G., Yu, M., Xiao, W., Celis, E. & Cui, Y. Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity. Cancer Res. 77, 2292–2305 (2017).
pubmed: 28280037
pmcid: 5465961
doi: 10.1158/0008-5472.CAN-16-2832
Attar, N. & Kurdistani, S. K. Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer. Cold Spring Harb. Perspect. Med. 7 (2017).
Fischer, K. et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109, 3812–3819 (2007).
pubmed: 17255361
doi: 10.1182/blood-2006-07-035972
Huang, H. et al. EP300-Mediated Lysine 2-Hydroxyisobutyrylation Regulates Glycolysis. Mol. Cell 70, 663–678.e6 (2018).
pubmed: 29775581
pmcid: 6029451
doi: 10.1016/j.molcel.2018.04.011
He, H. et al. Selective p300 inhibitor C646 inhibited HPV E6-E7 genes, altered glucose metabolism and induced apoptosis in cervical cancer cells. Eur. J. Pharmacol. 812, 206–215 (2017).
pubmed: 28619596
doi: 10.1016/j.ejphar.2017.06.005
Bowers, E. M. et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem. Biol. 17, 471–482 (2010).
pubmed: 20534345
pmcid: 2884008
doi: 10.1016/j.chembiol.2010.03.006
Chen, Y.-P. et al. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. Theranostics 7, 3585–3594 (2017).
pubmed: 28912897
pmcid: 5596445
doi: 10.7150/thno.21471
Cao, B., Wang, Q., Zhang, H., Zhu, G. & Lang, J. Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma. Oncoimmunology 7, e1392427 (2018).
pubmed: 29308323
doi: 10.1080/2162402X.2017.1392427
Lechner, A. et al. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. Oncotarget 8, 44418–44433 (2017).
pubmed: 28574843
pmcid: 5546490
doi: 10.18632/oncotarget.17901
Fang, J. et al. Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma. BMC Cancer 17, 375 (2017).
pubmed: 28549420
pmcid: 5446725
doi: 10.1186/s12885-017-3317-2
Dogan, V., Rieckmann, T., Münscher, A. & Busch, C.-J. Current studies of immunotherapy in head and neck cancer. Clin. Otolaryngol. Off. J. ENT-UK Off. J. Neth. Soc. Oto-Rhino-Laryngol. Cervico-Facial Surg. 43, 13–21 (2018).
Davis, A. A. & Patel, V. G. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. Immunother. Cancer 7, 278 (2019).
pubmed: 31655605
pmcid: 6815032
doi: 10.1186/s40425-019-0768-9
Cohen, E. E. W. et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J. Immunother. Cancer 7 (2019).
Zhang, X.-M. et al. Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma. Hum. Pathol. 82, 104–112 (2018).
pubmed: 30036594
doi: 10.1016/j.humpath.2018.07.012
Ramos, Y. F. M. et al. Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. Nucleic Acids Res. 38, 5396–5408 (2010).
pubmed: 20435671
pmcid: 2938195
doi: 10.1093/nar/gkq184
Smith, J. L. et al. Kinetic profiles of p300 occupancy in vivo predict common features of promoter structure and coactivator recruitment. Proc. Natl. Acad. Sci. USA 101, 11554–11559 (2004).
pubmed: 15286281
doi: 10.1073/pnas.0402156101
Chen, M.-K. et al. Overexpression of p300 correlates with poor prognosis in patients with cutaneous squamous cell carcinoma. Br. J. Dermatol. 172, 111–119 (2015).
pubmed: 24975674
doi: 10.1111/bjd.13226
Cho, Y.-A. et al. The role of p300 in the tumor progression of oral squamous cell carcinoma. J. Oral Pathol. Med. 44, 185–192 (2014).
pubmed: 25154636
doi: 10.1111/jop.12227
Kowalczyk, A. E. et al. Expression of the EP300, TP53 and BAX genes in colorectal cancer: Correlations with clinicopathological parameters and survival. Oncol. Rep. 38, 201–210 (2017).
pubmed: 28586030
doi: 10.3892/or.2017.5687
Li, M. et al. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J. Transl. Med. 9, 5 (2011).
pubmed: 21205329
pmcid: 3022728
doi: 10.1186/1479-5876-9-5
Ghosh, S. et al. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. J. Biol. Chem. 291, 13014–13027 (2016).
pubmed: 27056325
pmcid: 4933219
doi: 10.1074/jbc.M115.708560
Liu, Y. et al. Inhibition of p300 impairs Foxp3
pubmed: 23955711
pmcid: 3793393
doi: 10.1038/nm.3286
Wang, F., Marshall, C. B. & Ikura, M. Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition. Cell. Mol. Life Sci. 70, 3989–4008 (2013).
pubmed: 23307074
doi: 10.1007/s00018-012-1254-4
Haft, S. et al. Mutation of chromatin regulators and focal hotspot alterations characterize human papillomavirus-positive oropharyngeal squamous cell carcinoma. Cancer 125, 2423–2434 (2019).
pubmed: 30933315
doi: 10.1002/cncr.32068
Dogan, S. et al. Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx. Int. J. Cancer, https://doi.org/10.1002/ijc.32412 (2019).
Thomas, Y. & Androphy, E. J. Acetylation of E2 by P300 Mediates Topoisomerase Entry at the Papillomavirus Replicon. J. Virol. 93 (2019).
Jansma, A. L. et al. The high-risk HPV16 E7 oncoprotein mediates interaction between the transcriptional coactivator CBP and the retinoblastoma protein pRb. J. Mol. Biol. 426, 4030–4048 (2014).
pubmed: 25451029
pmcid: 4258470
doi: 10.1016/j.jmb.2014.10.021
Fera, D. & Marmorstein, R. Different regions of the HPV-E7 and Ad-E1A viral oncoproteins bind competitively but through distinct mechanisms to the CH1 transactivation domain of p300. Biochemistry 51, 9524–9534 (2012).
pubmed: 23121466
pmcid: 3521592
doi: 10.1021/bi3011863
Bernat, A., Avvakumov, N., Mymryk, J. S. & Banks, L. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 22, 7871–7881 (2003).
pubmed: 12970734
doi: 10.1038/sj.onc.1206896
Singer, K., Cheng, W.-C., Kreutz, M., Ho, P.-C. & Siska, P. J. Immunometabolism in cancer at a glance. Dis. Model. Mech. 11 (2018).
Theodoulou, N. H., Tomkinson, N. C., Prinjha, R. K. & Humphreys, P. G. Clinical progress and pharmacology of small molecule bromodomain inhibitors. Curr. Opin. Chem. Biol. 33, 58–66 (2016).
pubmed: 27295577
doi: 10.1016/j.cbpa.2016.05.028
Lasko, L. M. et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature 550, 128–132 (2017).
pubmed: 28953875
pmcid: 6050590
doi: 10.1038/nature24028
Pegg, N. et al. Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer. J. Clin. Oncol. 35, 11590–11590 (2017).
doi: 10.1200/JCO.2017.35.15_suppl.11590
Yan, Y. et al. Activity of NEO2734, a novel dual inhibitor of both BET and CBP-P300, in SPOP-mutated prostate cancer. J. Clin. Oncol. 37, 62–62 (2019).
doi: 10.1200/JCO.2019.37.7_suppl.62
Wang, Y.-M. et al. Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines. Int. J. Oncol. 51, 1860–1868 (2017).
pubmed: 29075795
doi: 10.3892/ijo.2017.4176